

# Christopher Seaman

T +1 (212) 365 - 8940  
E chris@badmath.org

## EXPERIENCE

*Head of Data Science* | **Bay View Analytics** 2023 - present  
Bio- and health-tech consulting with focus areas in digital health, diagnostics, therapeutics, and education. Results include analytical guidance through FDA approval and iterating ML solutions for improved efficacy and product/market-fit.

*Honorary Lecturer* | **UCSF** 2023 - present  
Taught data science applications in Python at UCSF's *Health Data Science Masters Program*. Course topics start include: SQL, data cleaning with Pandas, classification & model evaluation, vision, and building LLM's from scratch.

*Senior Advisor* | **Catalyst Accelerator Program** 2019 - present  
Advised portfolio companies and prospects on medical/health data science applications. Interviewed startups to improve their pitches, reviewed applications for grants/funding, and paired with select startups for long-term consulting.

*Director - Experimentation* | **1Password** 2022 - 2022  
Founded Experimentation and led Marketing Analytics. Designed/built A/B testing platform, hired data science team, and ran tests (multiple 20%+ wins). Owned top-of-funnel reporting, budget/forecasting, governance, and root cause analysis.

*Director - Data Science & Growth* | **Rollbar** 2020 - 2021  
Founded Growth and led Data Science. Set roadmaps & strategy, established experimentation platform & practices for A/B tests, features, and pricing. Improved ML error grouping (Rollbar's differentiator) by 35% and reduced noise by 80%.

*Founder* | **Monett** 2019 - 2019  
Co-founded a startup helping independent contractors with their banking and taxes. As head of product and research, I recruited and hired engineering & design and set sprint and epic priorities while building our MVP.

*Growth & Monetization Lead* | **Dropbox** 2017 - 2018  
Led PM's (10) responsible for Dropbox's individual plan paid conversion (majority of revenue) through IPO. Launched free trials for Dropbox mobile and redesigned the over-quota flow (where most free users convert) resulting in \$80m+ ARR lift.

*Data Science Lead* | **Atlassian** 2013 - 2017  
Founded and led data science team (5) through IPO. Owned A/B testing, attribution, causal inference, & ROAS resulting in 250,000+ MAU, millions saved in marketing. Recruited data engineering team (4) and marketing analytics (10).

*Experiment Design & Analysis* | **eBay** 2012 - 2013  
Designed methodologies for generative research on web-scale data. Created and extended tools for more informed planning efficiency in site-wide experimentation using standardized KPI's and user segments.

*Statistical Researcher* | **Human Services Research Institute** 2004 - 2006  
Designed outcomes-based model of mental health systems using Markov processes at this Harvard-affiliated research group. Conducted statistical and meta-analyses to improve patient outcomes through evidence-based policy.

*Bioinformatics Analyst* | **Whitehead Institute at MIT** 2001 - 2004  
Mapped portions of the human genome as a tiling path of bacterial artificial clones informed by disparate data sources & comparative genomics. Collaborated in publishing the Human Genome Project, with two articles in *Nature*.

## EDUCATION

*M.A. in Mathematics (Ph.D. all but dissertation)* | **City University of New York** 2010

*Bachelor of Arts in mathematics, cum laude* | **Wheaton College** 2002

## NONPROFIT

*Board of Directors, Governance Chair* | **Felton Institute** 2018 - 2021

## PUBLICATIONS

**Seaman C**, Allen IE, Seaman JE. Dissecting Discrimination. *Quality Progress*. 2020 August; 53 (8): 47-49.

**Seaman C**, Allen IE, Seaman JE. The Complete Picture. *Quality Progress*. 2019 February; 52 (2): 52-56.

Seaman JE, **Seaman C**, Allen IE. So Many Variables, So Few Observations. *Quality Progress*. 2013 September; 46 (9):34.

Reynolds M, Stephen R, **Seaman C**, Rajagopalan K. Persistence and Adherence to Disease Modifying Drugs Among Patients with Multiple Sclerosis, *Current Medical Research & Opinion*, 2010 March; 26 (3): 663-674.

Reynolds M, Stephen R, **Seaman C**, Rajagopalan K. Healthcare Resource Utilization Following Switch or Discontinuation in Multiple Sclerosis Patients on Disease Modifying Drugs, *Journal of Medical Economics*, 2010 March; 13 (1): 90-98.

**Seaman C**, Boklan KD, Dent AW. Broadcast Encryption with Multiple Trust Centers and Dynamic Coalitions, featured presentation at LatinCRYPT 2010, also presented at Annual Conference of the International Technology Alliance 2009.

Leff HS, Chow CM, Pepin R, Conley J, Allen IE, **Seaman C**. Does One Size Fit All? What We Can & Can't Learn from Meta-Analysis of Housing Models for Persons with Mental Illness, *Psychiatric Services*, 2009 April; 60 (4): 473-82.

Allen IE, **Seaman C**. Predicting Success, *Quality Progress*, 2009 February; 42 (2): 60-63.

Nordstrom BL, **Seaman C**, Reynolds MW, Rajagopalan K. Medical Costs Associated with Treatment Change in Multiple Sclerosis, presented at International Society For Pharmacoeconomics and Outcomes Research 13th Annual International Meeting, 2008 November.

Allen IE, **Seaman C**. The Trusty Jackknife, *Quality Progress*, 2008 July; 41 (7): 56-58.

Allen IE, **Seaman C**. Match Game, *Quality Progress*, 2008 February; 41(2): 56-58.

Allen IE, **Seaman C**, Data Mining in Quality and Reliability, chapter in *Encyclopedia of Statistics in Quality and Reliability*, edited by Fabrizio Ruggeri, Frederick Faltin, and Ron Kenett, John Wiley & Sons Ltd, 2008.

Reynolds M, **Seaman C**, Rajagopalan K, Roth E. Real-World Assessment of Patient Adherence and Treatment Discontinuation Among Different Treatments for Multiple Sclerosis, presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2007 October.

Allen IE, **Seaman C**. Likert Scales and Data Analyses, *Quality Progress*, 2007 July; 40 (7): 64-65.

Ross SD, Allen IE, Henry DH, **Seaman C**, Sercus B, Goodnough LT. Clinical Benefits and Risks Associated with Epoetin and Darbepoetin in Patients with Chemotherapy-Induced Anemia: A Systematic Review of the Literature, *Journal for Supportive Oncology*, 2007 April; 5 (4,supplement 2): 20-21.

Allen IE, **Seaman C**. Superiority, Equivalence and Non-Inferiority, *Quality Progress*, 2007 February; 40 (2).

Haas T (listed within article as Allen IE, **Seaman C**). Top Schools: 2006, *Philadelphia Magazine*, 2006 September.

Ross SD, Allen IE, Henry DH, **Seaman C**, Sercus B, Goodnough LT. Clinical Benefits and Risks Associated with Epoetin and Darbepoetin in Patients with Chemotherapy-Induced Anemia: A Systematic Review of the Literature, *Clinical Therapeutics*, 2006 June; 28(6): 801-31, presented at the 18th Annual Symposium of the Multinational Association of Supportive Care in Cancer, 2006 June.

Allen IE, **Seaman C**. Different, Equivalent or Both?, *Quality Progress*, 2006 July; 39 (7).

Olkin I, Allen IE, **Seaman C**. Hierarchical Modeling Using Individual Patient Meta-Analysis, presented at the New England Statistical Symposium, 2006 April.

Taylor T, et al (including **Seaman C**). Human chromosome 11 DNA Sequence and Analysis Including Novel Gene Identification, *Nature*, 2006 March 23, 440 (7083): 497-500.

Allen IE, **Seaman C**. Data Mining for Quality, *Quality Progress*, 2006 February; 39 (2).

Ozment K (in article as Allen IE, **Seaman C**). Smart Answers (the Best Schools), *Boston Magazine*, 2005 September.

Allen IE, **Seaman C**. Cumulative Meta-Analysis, *Quality Progress*, 2005 April; 38 (4), also *Babson Free Press*, 2005 May.

International Human Genome Sequencing Consortium (full author list in supplemental material). Finishing the Euchromatic Sequence of the Human Genome, *Nature*, 2004 October 21; 431(7011): 931-45.